Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B

Hemostatic management is essential for ensuring the safety of patients with hemophilia during surgery. This phase 3, prospective, uncontrolled trial, evaluated hemostatic efficacy, consumption, and safety of a recombinant factor IX concentrate, nonacog gamma (BAX 326, Rixubis(®) [Baxalta US Inc., a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Appl Thromb Hemost
Auteurs principaux: Windyga, Jerzy, Timofeeva, Margarita, Stasyshyn, Oleksandra, Mamonov, Vasily, Lamas Castellanos, José Luis, Lissitchkov, Toshko, Chojnowski, Krzysztof, Chapman, Miranda, Pavlova, Borislava G., Tangada, Srilatha
Format: Artigo
Langue:Inglês
Publié: SAGE Publications 2020
Sujets:
Original Manuscript
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444148/
https://ncbi.nlm.nih.gov/pubmed/32816519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029620946839
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires